Can adding immunotherapy boost a stomach cancer combo?

This trial is testing whether adding an immunotherapy drug called adebrelimab to a two-drug combination of apatinib and albumin-bound paclitaxel can help people with advanced stomach or gastroesophageal junction cancer. The study enrolls adults whose cancer has progressed after first-line treatment. Participants are randomly assigned to receive either the three-drug combo or the two-drug combo alone, and researchers will compare how long the cancer stays under control.